Royal Bank Of Canada Downgrades Smith & Nephew (LON:SN) to Sector perform

Smith & Nephew (LON:SN) was downgraded by equities researchers at Royal Bank Of Canada to a “sector perform” rating in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. They presently have a GBX 1,350 price objective on the stock, down from their prior price objective of GBX 1,700. Royal Bank Of Canada’s target price indicates a potential upside of 11.94% from the stock’s current price.

Several other equities research analysts also recently issued reports on SN. Panmure Gordon reissued a “hold” rating and issued a GBX 1,200 price objective on shares of Smith & Nephew in a research note on Tuesday, December 9th. Citigroup raised their price target on shares of Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Smith & Nephew in a research report on Friday, November 7th. Two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Smith & Nephew has a consensus rating of “Hold” and a consensus price target of GBX 1,381.33.

Smith & Nephew Stock Up 0.0%

SN opened at GBX 1,206 on Wednesday. The stock has a market capitalization of £13.22 billion, a price-to-earnings ratio of 43.42, a P/E/G ratio of 0.46 and a beta of 0.62. The firm has a 50-day simple moving average of GBX 1,298.60 and a two-hundred day simple moving average of GBX 1,259.88. The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84.

Insider Activity

In other news, insider Deepak Nath sold 1,240 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of GBX 1,257, for a total value of £15,586.80. Company insiders own 0.19% of the company’s stock.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.